Scarica l'app Stockscreener
16.03
1.78%
0.28
Dopo l'orario di chiusura:
17.26
1.23
+7.67%
Precedente Chiudi:
$15.75
Aprire:
$15.78
Volume 24 ore:
408.57K
Relative Volume:
1.96
Capitalizzazione di mercato:
$622.29M
Reddito:
$25.42M
Utile/perdita netta:
$-143.75M
Rapporto P/E:
-4.6184
EPS:
-3.4709
Flusso di cassa netto:
$-129.55M
1 W Prestazione:
+26.02%
1M Prestazione:
+15.49%
6M Prestazione:
+130.65%
1 anno Prestazione:
+92.44%
Intervallo 1D:
$15.00
$16.45
Intervallo di 1 settimana:
$12.56
$16.45
Portata 52W:
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
16.03 | 611.42M | 25.42M | -143.75M | -129.55M | -3.4709 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Oppenheimer | Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
Entrada Therapeutics to report phase 1/2 trial data Thursday By Investing.com - Investing.com Australia
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 - The Manila Times
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - Yahoo Finance
Entrada Therapeutics president & COO sells $229,953 in shares By Investing.com - Investing.com Canada
Entrada Therapeutics president & COO sells $229,953 in shares - Investing.com
Entrada Therapeutics (TRDA) R&D president sells 25,907 shares under 10b5-1 plan - Stock Titan
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics R&D president sells $398,809 in shares By Investing.com - Investing.com UK
Entrada Therapeutics R&D president sells $398,809 in shares - Investing.com
Morgan Stanley Smith Barney files TRDA Form 144; 15,000 shares sold (TRDA) - Stock Titan
TRDA (NASDAQ: TRDA) reports 25,907 RSUs to sell; insider sold March 2026 - Stock Titan
Entrada Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 12-Month HighWhat's Next? - MarketBeat
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday - MarketBeat
Is Entrada Therapeutics (TRDA) stock showing strong momentum | Q4 2025: EPS Tops ViewsIPO - Newser
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Entrada Therapeutics (NASDAQ: TRDA) details 2026 proxy and equity plan changes - Stock Titan
Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily
TRDA (Entrada Therapeutics) reports narrower Q4 2025 loss than expected, shares edge lower on steep revenue decline.Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring a Potential 52.97% Upside in the Biotech Sector - DirectorsTalk Interviews
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week HighShould You Buy? - MarketBeat
Sell Signal: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Buyback Activity & Long-Term Safe Investment Plans - baoquankhu1.vn
How Entrada Therapeutics Inc. (TRDA) Affects Rotational Strategy Timing - Stock Traders Daily
Entrada Therapeutics, Inc. $TRDA Stock Holdings Increased by JPMorgan Chase & Co. - MarketBeat
Investment Report: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
TRDA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Investor Mood: Does Entrada Therapeutics Inc have declining or rising EPS2026 AllTime Highs & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Entrada Therapeutics : Corporate Presentation April 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says - marketscreener.com
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating - marketscreener.com
Is Entrada Therapeutics (TRDA) Stock Undervalued Now | Price at $13.32, Up 1.32%Buy Zone Stocks - Newser
TRDA PE Ratio & Valuation, Is TRDA Overvalued - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock - marketbeat.com
Insider Sell Alert: Kory Wentworth Sells Shares of Entrada Thera - GuruFocus
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com - Investing.com Canada
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock - Investing.com
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
(TRDA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TRDA (NASDAQ: TRDA) insider 10b5‑1 sales listed, 11,388-share trade noted - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Cantor Fitzgerald Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-03-31 23:31:11 - baoquankhu1.vn
Risk Analysis: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc still a buy after recent gains2026 Retail & Capital Efficient Trade Techniques - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring a 65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):